Aspire Biopharma Holdings, Inc.(ASBP)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Rank #2,478 of 2,962 stocks
Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.
ASBP Stock Analysis & AI Quality Score
Data updated 2026-09-11AI stock analysis and institutional research for Aspire Biopharma Holdings, Inc. (ASBP), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores ASBP at 30.8/100 on a 32-signal composite quality model, placing it at rank #2,478 of 2,962 stocks — the bottom half of the AI-ranked universe. Based on the latest XBRL financial filings (Q2 2026), Aspire Biopharma Holdings, Inc. reports quarterly revenue of $63.1K, net income of $-1.3M. Top institutional holders of ASBP by reported 13-F value include JANE STREET GROUP, GEODE CAPITAL MANAGEMENT, VANGUARD CAPITAL MANAGEMENT, based on the most recent SEC filings. ASBP trades on the Nasdaq exchange and files with the SEC under CIK 1847345. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate ASBP daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Aspire Biopharma Holdings, Inc. directly from SEC EDGAR. Aspire Biopharma Holdings, Inc.'s 13F Pro composite quality score has ranged between 30 and 41 since 2026, currently 30.8 — a declining long-term trajectory across 8 quarterly and live scoring snapshots.
Revenue
Q2 2026
$63.1K
Net Income
Q2 2026
$-1.3M
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · ProRevenue
Net Income
-1768.9% YoYOperating Income
-1498.1% YoYEPS (Diluted)
-762.1% YoYTotal Assets
+786.7% YoYOp. Cash Flow
-1756.6% YoY| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $6.2K | — | — | — | — |
| Net Income | $-24.5M -1768.9% | $-1.3M -129.3% | $4.5M +33.6% | $3.3M | — |
| Operating Income | $-19.4M -1498.1% | $-1.2M | — | — | — |
| EPS (Diluted) | $-16.38 -762.1% | $-1.90 | — | — | — |
| Total Assets | $1.3M +786.7% | $148.0K -99.3% | $20.0M -93.3% | $300.2M +102274.0% | $293.2K |
| Operating Cash Flow | $-4.9M -1756.6% | $-265.2K +59.4% | $-653.1K +53.6% | $-1.4M | — |
Get alerted when ASBP's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for Aspire Biopharma Holdings, Inc. including:
Top Institutional Holders of ASBP
JANE STREET GROUP, LLC
$79.2K14,830 shGEODE CAPITAL MANAGEMENT, LLC
$55.9K10,474 shVANGUARD CAPITAL MANAGEMENT LLC
$55.6K10,408 shVANGUARD FIDUCIARY TRUST CO
$53.8K10,081 shSaba Capital Management, L.P.
$22.9K983,603 shADAGE CAPITAL PARTNERS GP, L.L.C.
$21.0K1,050,000 shLINDEN ADVISORS LP
$21.0K899,999 shARISTEIA CAPITAL, L.L.C.
$15.9K681,516 shTORONTO DOMINION BANK
$10.3K516,245 shSculptor Capital LP
$10.0K500,000 sh
| Fund | Value | Shares |
|---|---|---|
| JANE STREET GROUP, LLC | $79.2K | 14,830 |
| GEODE CAPITAL MANAGEMENT, LLC | $55.9K | 10,474 |
| VANGUARD CAPITAL MANAGEMENT LLC | $55.6K | 10,408 |
| VANGUARD FIDUCIARY TRUST CO | $53.8K | 10,081 |
| Saba Capital Management, L.P. | $22.9K | 983,603 |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | $21.0K | 1,050,000 |
| LINDEN ADVISORS LP | $21.0K | 899,999 |
| ARISTEIA CAPITAL, L.L.C. | $15.9K | 681,516 |
| TORONTO DOMINION BANK | $10.3K | 516,245 |
| Sculptor Capital LP | $10.0K | 500,000 |
More Healthcare Companies
View all Healthcare →Put ASBP on your watchlist
Track score changes the day Aspire Biopharma Holdings, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is ASBP a good stock to buy?
13F Pro's AI-powered analysis of Aspire Biopharma Holdings, Inc. (ASBP) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for ASBP are available on the ASBP stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. ASBP is classified as a small company.
Which hedge funds own ASBP?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling ASBP. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Aspire Biopharma Holdings, Inc.'s investment landscape.